Development of a colloidal gold-based immunochromatographic strip test using two monoclonal antibodies to detect H7N9 avian influenza virus

Yang, Fan; Xiao, Yixin; Chen, Bin; Wang, Liyan; Liu, Fumin; Yao, Hang‐Ping; Wu, Nanping; Wu, Haibo

doi:10.1007/s11262-020-01742-8

Cited by 16 publications

(15 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The advantages of using mAbs for detecting AIV include high specificity, sensitivity and unlimited provision of a standardized reagent. mAbs against the HA protein of AIV served as a useful tool to distinguish its subtypes in previous studies [22][23][24]. In the present paper, the cELISA immunoassay for H7 antibody detection was developed using an anti-H7-HA1 mAb targeting the epitope located in the depression under antigenic site E of H7-HA1 subunit [17].…”

Section: Discussionmentioning

confidence: 99%

Development and evaluation of a monoclonal antibody-based competitive ELISA for the detection of antibodies against H7 avian influenza virus

Meng

et al. 2021

BMC Vet Res

View full text Add to dashboard Cite

Background H7 subtype avian influenza has caused great concern in the global poultry industry and public health. The conventional serological subtype-specific diagnostics is implemented by hemagglutination inhibition (HI) assay despite lengthy operation time. In this study, an efficient, rapid and high-throughput competitive enzyme-linked immunosorbent assay (cELISA) was developed for detection of antibodies against H7 avian influenza virus (AIV) based on a novel monoclonal antibody specific to the hemagglutinin (HA) protein of H7 AIV. Results The reaction parameters including antigen coating concentration, monoclonal antibody concentration and serum dilution ratio were optimized for H7 antibody detection. The specificity of the cELISA was tested using antisera against H1 ~ H9, H11 ~ H14 AIVs and other avian viruses. The selected cut-off values of inhibition rates for chicken, duck and peacock sera were 30.11, 26.85 and 45.66% by receiver-operating characteristic (ROC) curve analysis, respectively. With HI test as the reference method, the minimum detection limits for chicken, duck and peacock positive serum reached 20, 21 and 2− 1 HI titer, respectively. Compared to HI test, the diagnostic accuracy reached 100, 98.6, and 99.3% for chicken, duck and peacock by testing a total of 400 clinical serum samples, respectively. Conclusions In summary, the cELISA assay developed in this study provided a reliable, specific, sensitive and species-independent serological technique for rapid detection of H7 antibody, which was applicable for large-scale serological surveillance and vaccination efficacy evaluation programs.

show abstract

Section: Discussionmentioning

confidence: 99%

Development and evaluation of a monoclonal antibody-based competitive ELISA for the detection of antibodies against H7 avian influenza virus

Meng

et al. 2021

BMC Vet Res

View full text Add to dashboard Cite

show abstract

“…The advantages of using mAbs for detecting AIV include high speci city, sensitivity and unlimited provision of a standardized reagent. mAbs against the HA protein of AIV served as a useful tool to distinguish its subtypes in previous studies [21][22][23]. In the present paper, the cELISA immunoassay for H7 antibody detection was developed using an anti-H7-HA1 mAb targeting the epitope located in the depression under antigenic site E of H7-HA1 subunit [17].…”

Section: Discussionmentioning

confidence: 99%

Development and evaluation of a monoclonal antibody-based competitive ELISA for the detection of antibodies against H7 avian influenza virus

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: H7 subtype avian influenza have caused great concern in the global poultry industry and public health. The conventional serological subtype-specific diagnostics is implemented by hemagglutination inhibition (HI) assay despite lengthy operation time. In this study, an efficient, rapid and high-throughput competitive enzyme-linked immunosorbent assay (cELISA) was developed for detection of antibodies against H7 avian influenza virus (AIV) based on a novel monoclonal antibody specific to the hemagglutinin (HA) protein of H7 AIV. Results: The reaction parameters including antigen coating concentration, monoclonal antibody concentration and serum dilution ratio were optimized for H7 antibody detection. The specificity of the cELISA was tested using antisera against H1~H9, H11~H14 AIVs and other avian viruses. The selected cut-off values of inhibition rates for chicken, duck and peacock sera were 30.11%, 26.85% and 45.66% by receiver-operating characteristic (ROC) curve analysis, respectively. With HI test as the reference method, the minimum detection limits for chicken, duck and peacock positive serum reached 2 0 , 2 1 and 2 -1 HI titer, respectively. Compared to HI test, the diagnostic accuracy reached 100%, 98.6%, and 99.3% for chicken, duck and peacock by testing a total of 400 clinical serum samples, respectively. Conclusions: In summary, the cELISA assay developed in this study provided a reliable, specific, sensitive and species-independent serological technique for rapid detection of H7 antibody, which was applicable for large-scale serological surveillance and vaccination efficacy evaluation programs.

show abstract

“…2b). Recently, AuNP-LF was employed for the detection of Influenza A and B virus [114], Rice stripe virus (RSV) [115], Newcastle disease virus (NDV) [116], H7N9 avian influenza virus [115], avian leukosis virus [117], and laryngotracheitis virus (ILTV) [118]. Following SARS-CoV-2 infection, IgM appears in blood samples a few days after the onset of initial symptoms .…”

Section: Nanobiomaterials-based Biosensors For the Diagnosis Of Covid-19mentioning

confidence: 99%

Role of biomaterials in the diagnosis, prevention, treatment, and study of corona virus disease 2019 (COVID-19)

et al. 2021

View full text Add to dashboard Cite

Recently emerged novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting corona virus disease 2019 (COVID-19) led to urgent search for methods to prevent and treat COVID-19. Among important disciplines that were mobilized is the biomaterials science and engineering. Biomaterials offer a range of possibilities to develop disease models, protective, diagnostic, therapeutic, monitoring measures, and vaccines. Among the most important contributions made so far from this field are tissue engineering, organoids, and organ-on-a-chip systems, which have been the important frontiers in developing tissue models for viral infection studies. Also, due to low bioavailability and limited circulation time of conventional antiviral drugs, controlled and targeted drug delivery could be applied alternatively. Fortunately, at the time of writing this paper, we have two successful vaccines and new at-home detection platforms. In this paper, we aim to review recent advances of biomaterial-based platforms for protection, diagnosis, vaccination, therapeutics, and monitoring of SARS-CoV-2 and discuss challenges and possible future research directions in this field.

show abstract

Development of a colloidal gold-based immunochromatographic strip test using two monoclonal antibodies to detect H7N9 avian influenza virus

Cited by 16 publications

References 33 publications

Development and evaluation of a monoclonal antibody-based competitive ELISA for the detection of antibodies against H7 avian influenza virus

Development and evaluation of a monoclonal antibody-based competitive ELISA for the detection of antibodies against H7 avian influenza virus

Development and evaluation of a monoclonal antibody-based competitive ELISA for the detection of antibodies against H7 avian influenza virus

Role of biomaterials in the diagnosis, prevention, treatment, and study of corona virus disease 2019 (COVID-19)

Contact Info

Product

Resources

About